Protocol T: Comparing Anti-VEGFs for DME

In this interview from AAO 2015, Dr. John Wells discusses results from the Diabetic Retinopathy Clinical Research Network’s (DRCR.net) comparative effectiveness study, which showed that aflibercept may be more effective than other anti-VEGFs in patients with diabetic macular edema, but only in those with worse baseline visual acuity. The multicenter, randomized trial known as Protocol T evaluated the relative efficacy and safety of intravitreal aflibercept, bevacizumab and ranibizumab for center-involving diabetic macular edema.